ArticleNew microbes and new infections2026
Association of COVID-19 with risks of all-cause and cause-specific mortality post-infection: A UK Biobank cohort study.
Article in New microbes and new infections, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: While SARS-CoV-2 causes multi-organ complications, comprehensive assessments of long-term mortality across organ systems remain limited. This study systematically evaluated COVID-19's impact on all-cause and cause-specific mortality. Methods: This cohort study followed 467,522 UK Biobank participants (Jan2020-Dec2022). COVID-19 exposure (representing clinically apparent infection) was classified as overall, hospitalized, and non-hospitalized, and compared with reference cohort without documented SARS-CoV-2 records. Post-acute mortality (>30 days post-infection) was assessed using landmark analyses; overall-mortality (including acute-phase deaths) was evaluated as secondary analyses and presented in Supplementary Materials. Adjusted Cox models estimated risks for 12 organ systems and 47 diseases, with subgroup analyses by key comorbidities and demographics. Results: Post-acute all-cause mortality was elevated in overall (hazard ratio [HR]: 1.50) and hospitalized (HR: 3.06) COVID-19 cohorts, but not non-hospitalized group. COVID-19 infection increased post-acute mortality from circulatory, digestive, genitourinary, neurological, respiratory, and external causes, as well as neoplasms (though elevated cancer mortality without prior diagnoses may reflect detection bias). Hospitalized cases showed elevated risks across 11/11 organ systems and 27/37 diseases; non-hospitalized cases showed increased risks for external-cause and neurological outcomes. Advanced age, atrial fibrillation, chronic kidney disease, and hypertension exacerbated post-acute all-cause mortality; atrial fibrillation also amplified respiratory and neurological risks. Conclusion: Clinically apparent COVID-19 was associated with elevated post-acute mortality across multiple systems, with hospitalized cases exhibiting the broadest risk spectrum. As controls may include unrecorded infections, these estimates are likely conservative. Sustained monitoring is warranted, particularly for older survivors and those with high-risk comorbidities.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.